

10/533300

JC17 Rec'd PCT/PTO 29 APR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MEDER *et al.*

Appl. No.: (to be assigned; U.S. National
Phase of PCT/EP2003/011799)

Int'l Filing Date: October 24, 2003

For: **Human Chondroosteomodulin
(TIG2), Production, and Use for the
Treatment or Diagnosis of Bone
Diseases, Cartilage Diseases,
Obesity, Inflammatory Diseases,
and Skin Diseases**

Confirmation No.: (to be assigned)

Art Unit: (to be assigned)

Examiner: (to be assigned)

Atty. Docket: 2388.0010000/SRL/BLS

Preliminary Amendment and Submission of Sequence Listing

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying

this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.